---

---

tags : Cancer    source : Www.prnewswire.com   

save search

---

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-04-23 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K |

Manufacturing

| -0.21% | O: -1.05% H: 0.85% C: 0.85%
TAK | News | $13.23 -1.12% 0.0% 920K |

Health Technology

| -0.86% | O: -0.19% H: 0.08% C: -0.68%
granted approval cancer treatment for

---

RSNA and GE HealthCare Bring Advanced Mammography Technology to Tanzania to Improve Access and Help Address Breast Cancer Mortality Rate
Published: 2024-04-16 (Crawled : 12:00) - prnewswire.com
GEHC | $86.665 0.49% 0.49% 2M |

n/a

| -0.93% | O: -1.94% H: 0.71% C: 0.06%
breast cancer technology advanced

---

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Published: 2024-04-03 (Crawled : 12:30) - prnewswire.com
GNPX | $2.31 6.77% 20K |

Health Technology

| -22.18% | O: 1.76% H: 13.15% C: 7.61%
reqorsa lung cancer treat cell trial therapy study

---

BIO-TECHNE TO PRESENT AT THE 2024 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) CONFERENCE
Published: 2024-04-03 (Crawled : 11:00) - prnewswire.com
TECH | $63.48 -0.33% -0.33% 980K |

Health Technology

| -7.62% | O: -0.68% H: 0.7% C: -0.62%
conference association cancer research

---

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Published: 2024-04-02 (Crawled : 05:00) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| -3.16% | O: -2.79% H: 1.32% C: 1.18%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -2.71% | O: -1.14% H: 0.02% C: -1.06%
review cancer treatment advanced china

---

Turbine and Harmonic Discovery Pair Simulation-Guided Biology and Multi-Target Kinase Inhibition Chemistry Expertise to Develop a Novel Cancer Therapy
Published: 2024-04-01 (Crawled : 11:00) - prnewswire.com
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -6.33% | O: -0.28% H: 0.27% C: 0.04%
cancer therapy

---

Maverix Medical Closes Acquisition of Cirrus Bio as Foundation for Diagnostics Platform in Lung Cancer
Published: 2024-03-29 (Crawled : 12:30) - prnewswire.com
HOLX | $76.71 -0.62% -0.63% 910K |

Health Technology

| Email alert Add to watchlist
lung cancer acquisition medical diagnostics foundation platform

---

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-03-28 (Crawled : 15:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K |

Manufacturing

| -13.44% | O: 0.82% H: 0.0% C: -2.54%
keytruda license bladder cancer treatment medical application advanced

---

Global Particle Therapy Market Analysis and Forecasts, 2023-2033 : Revolutionizing Cancer Treatment, Particle Therapy's Rise in External Beam Radiotherapy
Published: 2024-03-27 (Crawled : 23:00) - prnewswire.com
BSGM | $1.32 -10.81% -12.12% 150K |

Health Technology

| 85.65% | O: 3.94% H: 4.19% C: -10.55%
cancer global therapy market

---

Innovent Dosed First Participant in Phase 3 Clinical Study (Neoshot) of IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab for MSI-H/dMMR Colon Cancer Neoadjuvant Therapy
Published: 2024-03-27 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -5.96% | O: -0.26% H: 0.0% C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| -2.93% | O: 0.49% H: 0.84% C: -0.07%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -3.57% | O: 1.06% H: 0.0% C: 0.0%
INCY | $51.72 0.14% 0.14% 1.5M |

Health Technology

| -8.51% | O: -0.09% H: 1.42% C: 1.1%
ibi310 first cancer colon therapy study

---

Ambetter from Sunshine Health and Tampa Bay Buccaneers Tackle Colorectal Cancer During Colorectal Cancer Awareness Month
Published: 2024-03-26 (Crawled : 23:00) - prnewswire.com
CNC | $76.19 0.46% 0.0% 2.8M |

Health Services

| -1.77% | O: 0.63% H: 0.82% C: 0.38%
bay health cancer

---

Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
Published: 2024-03-26 (Crawled : 12:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K |

Manufacturing

| -13.12% | O: -1.65% H: 3.36% C: 3.17%
japan approved cancer treatment

---

Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.
Published: 2024-03-25 (Crawled : 15:00) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K |

Health Technology

| -0.4% | O: -100.0% H: NaN% C: Infinity%
NVS | News | $98.35 1.1% 0.0% 2.2M |

Health Technology

| 2.2% | O: -0.08% H: 0.15% C: -0.44%
LLY | News | $732.2 -1.81% 0.18% 2.1M |

Health Technology

| -2.39% | O: 0.06% H: 0.96% C: 0.26%
CAH | $103.54 0.16% -0.52% 2.1M |

Distribution Services

| -6.73% | O: 0.02% H: 0.73% C: -0.02%
LNTH | $65.19 1.21% 1.2% 580K |

Health Technology

| 10.49% | O: 0.1% H: 1.98% C: -0.08%
reach cancer treatment market

---

Philadelphia Phillies partner with the National Pediatric Cancer Foundation® for "Cut and Color Funds the Cure®"
Published: 2024-03-23 (Crawled : 00:20) - prnewswire.com
FNCTF | News | $11.16 -20.84% 130 |

Communications

| Email alert Add to watchlist
foundation cancer

---

U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients
Published: 2024-03-22 (Crawled : 19:00) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M |

Health Technology

| Email alert Add to watchlist
elahere drug approval food cancer grants

---

Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-03-22 (Crawled : 12:00) - prnewswire.com
ALPMF | News | $9.5 43.47% 1.2K |

Health Technology

| -14.34% | O: -0.54% H: 0.0% C: 0.0%
ALPMY | News | $9.49 -1.11% 480K |

Manufacturing

| -14.45% | O: 2.26% H: 0.0% C: -2.65%
chmp positive cancer treatment

---

Microsoft and Paige's Collaboration Set to Transform Cancer Diagnosis in U.S. AI Medical Imaging Market - Forecasts to 2030
Published: 2024-03-19 (Crawled : 14:30) - prnewswire.com
NNOX | News | $9.105 -2.2% -2.25% 630K |

Health Technology

| -20.12% | O: -3.08% H: 1.72% C: -1.9%
AMD | $151.68 -0.39% -0.39% 43M |

Electronic Technology

| -20.41% | O: -3.93% H: 1.34% C: -0.95%
cancer collaboration set medical imaging market

---

IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
Published: 2024-03-19 (Crawled : 12:30) - prnewswire.com
ICCM | $1.22 0.82% 94K |

Manufacturing

| 0.83% | O: 2.07% H: 0.0% C: 0.0%
free company breast one positive cancer women topline medical alternative results

---

Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Published: 2024-03-19 (Crawled : 07:00) - prnewswire.com
FUSN | $21.4 -0.09% -0.09% 270K |

Health Technology

| 101.13% | O: 96.99% H: 1.19% C: 1.05%
cancer treat pharmaceuticals acquired

---

Global Neutropenia Market Poised to Reach USD 5.86 Billion by 2028, Amid Rising Cancer Incidence and Advancements in Treatment Options
Published: 2024-03-18 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -0.94% | O: -0.02% H: 0.0% C: 0.0%
BAX | $40.93 -0.22% 0.0% 2.2M |

Health Technology

| -1.47% | O: 0.02% H: 1.03% C: 0.96%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| -1.22% | O: -1.51% H: 0.0% C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M |

Health Technology

| -8.44% | O: 0.11% H: 0.59% C: 0.1%
BIIB | $201.91 4.52% 4.32% 3.3M |

Health Technology

| -7.94% | O: -0.48% H: 0.31% C: 0.13%
reach cancer treatment global market

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---